2005.03.01. Dr. Pogány - WHO, Shanghai 1/35 Workshop on Quality Assurance and GMP of Multisource HIV/AIDS medicines János Pogány, pharmacist, PhD, consultant.

Slides:



Advertisements
Similar presentations
Development of ARV FDC for Pediatric use Alan Parr, Pharm.D., Ph.D. GlaxoSmithKline Research Triangle Park, NC.
Advertisements

Slide 1 of 16 Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community Dar Es.
Finished Pharmaceutical Product Specifications
Stability data required by WHO-PQP Mercy Acquaye.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Experience of Pre-Qualification Program.
Prequalification and Quality Monitoring of anti-malaria products Andre van Zyl, M. Pharm. Project Manager Health Technology and Pharmaceuticals Cluster,
WHO Training Course on Prequalification Introduction Efficacy and Safety Issues Hans Kemmler Consultant to WHO Accra, 5.Nov
1 XXXXXXXXXXXXXXXXXXX, Malaysia, XXXXXX September, S.3.2 Impurities, Malaysia, 29 September 2011 Options for submitting API data to support.
Determine impurity level in relevant batches1
Quality control of raw materials In-process control
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Pogány - Guilin 1/36 WHO Training Workshop on Pharmaceutical Quality, G MP and Bioequivalence with a focus on artemisinines János Pogány, pharmacist,
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Variations Maintenance of Prequalified.
Variations to Prequalified Medicines Rutendo Kuwana Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Reference, Retention and Reserve Samples
STABILITY STUDIES GABRIEL K. KADDU
TANZANIA August Note on Choice of Comparator Products: Current status Note to Applicants on Choice of Comparator Products in the Prequalification.
Dr. Pogány - WHO, Bangkok 1/71 QUALITY MANAGEMENT OF ANTIMALARIAL MEDICINES János Pogány, Ph.D., WHO consultant Bangkok, 19 October
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
II Workshop on Medicines Regulation in the Caribbean Region Barbados, September 8 th and 9 th, 2009 Se1 II Workshop on Medicines Regulation in the Caribbean.
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
Slide 1 of 18D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Structure of Dossier of Medicinal Product- Q part
Dr. Pogány - Guilin 1/61 WHO Training Workshop on Pharmaceutical Quality, G MP and Bioequivalence with a focus on artemisinines János Pogány,
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
| Slide 1 of 33 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront.
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Quality Control Testing in Procurement Helene Möller, M.Pharm, PhD Interregional Seminar for Quality Control Laboratories involved in WHO Prequalification.
Theo Dekker -- Jiaxing, China --September |2 | WHO workshop on Quality, good manufacturing practice and bioequivalence with a focus on antituberculotics.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
1 TG Dekker – WHO, MalaysiaFeb 2005 Experience with Prequalification of Dossiers (quality part) Workshop on GMP and Quality Assurance of Multisource Tuberculosis.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.
WHO Workshop on Assessment of Bioequivalence Data BCS-Biowaivers - Template Dr. Henrike Potthast WHO Workshop on Assessment of.
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
Lynda Paleshnuik | January |1 | Quality Workshop Copenhagen – January 2012 Training session Outline and Objectives.
Theo Dekker -- CPH -- Nov |2 | Meeting of WHO PQP with European manufacturers and EU holders of marketing authorisations WHO Prequalification of.
Assessment of Interchangeable Multisource Medicines BCS-Biowaivers - Template Dr. Henrike Potthast Training workshop: Assessment of.
Overview of FDA's Regulatory Framework for PET Drugs
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 The new PQP quality guideline.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.
Pogány - Tanzania 1/36 WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence János Pogány, pharmacist, PhD consultant to.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
Pogány - Hanoi 1/40 Training Workshop on Pharmaceutical Quality and Bioequivalence, January 2006 János Pogány, pharmacist, Ph.D. consultant.
TANZANIA AUGUST TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININS.
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Deficiencies in Bioequivalence dossiers Overview and Examples.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Pharmaceutical Development Applications.
Dr. Pogány - Geneva 1/30 PREQUALIFICATION OF ANTIMALARIAL DRUG PRODUCTS János Pogány, pharmacist, Ph.D. Geneva, 03 May 2004
Dr. Pogány - WHO, Shanghai 1/62 Workshop on Quality Assurance and GMP of multisource HIV/AIDS medicines János Pogány, pharmacist, PhD, consultant.
Stability Studies : Regulatory evaluation and most frequently observed Sultan Ghani.
VICH Guidelines: Stability Testing of New Veterinary Drug Substances and Medicinal Products Mai Huynh U.S. FDA Center for Veterinary Medicine Washington.
1 |1 | WHO Prequalification – Medicines Assessments Andrew Chemwolo, Technical Officer Prequalification Team – Medicines Assessment.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
WHO Technical Report Series, No. 953, 2009
Prequalification of essential medicines
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
Prequalification of HIV/AIDS products and manufacturers
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
Presentation transcript:

Dr. Pogány - WHO, Shanghai 1/35 Workshop on Quality Assurance and GMP of Multisource HIV/AIDS medicines János Pogány, pharmacist, PhD, consultant to WHO Shanghai, 01 March Experience with prequalification of HIV/AIDS products: product dossier assessment

Dr. Pogány - WHO, Shanghai 2/35 ABBREVIATIONS and NOTES API(s)Active pharmaceutical ingredient(s) ARVAntiretroviral EOIExpression of interest FPP(s)Finished pharmaceutical product(s) ICHInternational Conference on Harmonization MLEMModel List of Essential Medicines NDRANational Drug Regulatory Authority Ph.Eur.European Pharmacopoeia IPInternational Pharmacopoeia USPUnited States Pharmacopeia Text in green refers to WHO guidelines or requirements Text in yellow indicates an assessment issue

Dr. Pogány - WHO, Shanghai 3/35 SUBJECTS FOR DISCUSSION 1.Interchangeability of FPPs 2.Classification of ARV FPPs 3.Deficiencies observed in the evaluation of dossiers  Regulatory issues  Correspondence with FPP manufacturers 4.Conclusions

INTERCHANGEABILITY OF FPPs Pharmaceutical equivalence

Dr. Pogány - WHO, Shanghai 5/35 INTERCHANGEABILITY (IC) INTERCHANGEABILITY (IC) OF MULTISOURCE FPPs = (ESSENTIAL SIMILARITY WITH INNOVATOR FPP) = PHARMACEUTICAL EQUIVALENCE ( PE ) + BIOEQUIVALENCE (BE) IC = PE + BE

Dr. Pogány - WHO, Shanghai 6/35 PHARMACEUTICAL EQUIVALENCE  FPPs MEET SAME OR COMPARABLE STANDARDS (pharmacopoeia, marketing authorization)  SAME API (chemical and physical equivalence)  SAME DOSAGE FORM AND ROUTE OF ADMINISTRATION  SAME STRENGTH  COMPARABLE LABELING  WHO-GMP (batch-to-batch uniformity of quality)  STABILITY EQUIVALENCE

Dr. Pogány - WHO, Shanghai 7/35 INACTIVE INGREDIENTS ACTIVE INGREDIENTS PACKING MATERIALS FPP MANUFACTURER Manufacturin g authorization Marketing authorization GMP standards Pharmacopei astandards NATIONAL DRA1 NATIONAL DRA2 FACTORS INFLUENCING PE

Classification of ARV FPPs 13th MODEL LIST OF ESSENTIAL MEDICINES and EXPRESSION OF INTEREST (January 2004)

Dr. Pogány - WHO, Shanghai 9/35 BLUE BOOK DEFINITIONS MULTISOURCE 1 (generic) pharmaceutical products are pharmaceutically equivalent products that may or may not be therapeutically equivalent. Multisource pharmaceutical products that are therapeutically equivalent are interchangeable. 1 Many manufacturers by definition.

Dr. Pogány - WHO, Shanghai 10/35 BLUE BOOK DEFINITIONS WELL-ESTABLISHED drug products  have been marketed for at least five years in countries that undertake active post­marketing monitoring;  have been widely used to permit the assumption that safety and efficacy are well known; and  have the same route of administration and strength, and the same or similar indications as in those countries where the innovator FPP was approved.

Dr. Pogány - WHO, Shanghai 11/35 WELL-ESTABLISHED CRITERION  Zidovudine (Retrovir™, 19 March 1987* )*  Didanosine (Videx™, 9 October 1991*)*  Stavudine  Stavudine (Zerit™, 24 June 1994*)*  Lamivudine (Epivir™, 17 November 1995*)*  Saquinavir (Invirase™, 6 December 1995*)*  Indinavir (Crixivan™, 13 March 1996*)*  Nevirapine (Viramune™, 21 June 1996*)*  Ritonavir (Norvir™, 1 March 1996*)* * Approval date of the first pharmaceutical dosage form for sales in the USA

Dr. Pogány - WHO, Shanghai 12/35 WELL-ESTABLISHED CRITERION  Nelfinavir (Viracept™, 14 March 1997*)*  Abacavir (Ziagen™, 17 December 1998 *)*  Efavirenz (Sustiva™, 17 September 1998 *)*  Lopinavir + Ritonavir (Kaletra™, 15 September 2000 *)*  Tenofovir (new class, Viread™, 26 October 2001* )* * Approval date of the first pharmaceutical dosage form for sales in the USA

Dr. Pogány - WHO, Shanghai 13/35 FIXED-DOSE COMBINATIONS (EOI) 1 STAVUDINE  LAMIVUDINE + STAVUDINE  LAMIVUDINE + ZIDOVUDINE STAVUDINE  LAMIVUDINE + STAVUDINE + EFAVIRENZ STAVUDINE  LAMIVUDINE + STAVUDINE + NEVIRAPINE  LAMIVUDINE + ZIDOVUDINE + EFAVIRENZ  LAMIVUDINE + ZIDOVUDINE + NEVIRAPINE 1 There is n o innovator for the above FDCs. Well-established criterion refers to co-administration.

Dr. Pogány - WHO, Shanghai 14/35 CLASSIFICATION MATRIX Market availability of FPP Therapeutic experience Quality standard Monopoly Limited to well established Innovator’s specification Oligopoly Less than five yearsIn-house generic specification Oligopoly, innovator exists Well establishedIn-house generic specification Oligopoly, innovator does not exist Well establishedIn-house generic specification MultisourceWell establishedOfficial compendia

Dr. Pogány - WHO, Shanghai 15/35 ARV APIs and FPPs  are typically available from more than one manufacturer but not always from many suppliers;  except (Lopinavir + Ritonavir) and Tenofovir, others are well-established by WHO criteria;  FPPs contain an API not yet official in an internationally recognized pharmacopoeia.

Dr. Pogány - WHO, Shanghai 16/35 LOW-RISK APIs 1.CERTIFICATE OF SUITABILITY (DRA) 2.DRUG MASTER FILE  OPEN PART (APPLICANT)  CLOSED PART (DRA) 3.PHARMACOPEIA MONOGRAPH  LITERATURE EVIDENCE OF STABILITY  SYNTHESIS IMPURITIES ARE CONTROLLED BY MONOGRAPH (toxicology of additional impurities)  CLASS1 SOLVENTS EXCLUDED, CLASS2 SOLVENTS CONTROLLED 4.FPP IS REGISTERED IN THE ICH REGION

Dr. Pogány - WHO, Shanghai 17/35 HIGH-RISK APIs and FPPs  Reference standard/comparator is not available for :  Pharmaceutical equivalence studies  Bioequivalence studies  APIs and FPPs are not official in the internationally used major pharmacopoeias  WHO guides/SOPs apply to multisource FPPs. ICH guides should be used for evaluation.  Require particular attention by NDRA as regards assessment of applications for marketing authorization.

Dr. Pogány - WHO, Shanghai 18/35 HIGH-RISK ARV APIs  Abacavir  Efavirenz  Indinavir  Lopinavir  Nelfinavir  Ritonavir  Stavudine  Tenofovir

Dr. Pogány - WHO, Shanghai 19/35 HIGH-RISK ARV FPPs  ABACAVIR tablets 300mg, oral solution 20 mg/ml  TENOFOVIR tablets 300mg STAVUDINE  LAMIVUDINE + STAVUDINE  LAMIVUDINE + ZIDOVUDINE STAVUDINE  LAMIVUDINE + STAVUDINE + EFAVIRENZ STAVUDINE  LAMIVUDINE + STAVUDINE + NEVIRAPINE  LAMIVUDINE + ZIDOVUDINE + EFAVIRENZ  LAMIVUDINE + ZIDOVUDINE + NEVIRAPINE

Deficiencies observed in the evaluation of dossiers REGULATORY ISSUES

Dr. Pogány - WHO, Shanghai 21/35 GLOBAL ISSUES API or FPP originate „LEGALLY” from countries where:  Manufacture of APIs is not regulated  Pharmaceutical exports and imports are not regulated  Marketing Authorizations [MA(s)] of FPPs are issued without evaluation by the national drug regulatory authority (NDRA) for locally developed and manufactured FPPs,  Nevertheless, WHO-type certificates are issued

Dr. Pogány - WHO, Shanghai 22/35 GLOBAL ISSUES  Pharmaceutical R + D studies are not yet required for MA  Stability studies were not required for MA  Validation studies are not yet required for MA  Bioequivalence studies are not yet required for MA  National Good Manufacturing Practices are not commensurate WHO-GMP requirements

Deficiencies observed in the evaluation of dossiers ILLUSTRATIVE EXAMPLES FROM CORRESPONDENCE WITH MANUFACTURERS

Dr. Pogány - WHO, Shanghai 24/35 CRITICAL API DEFICIENCIES  Synthesis impurities, including residual solvents, which may be present in API, were not characterised and analysed.  Residual solvents were included in the DMF but not in the API specification (skip testing).  Class2 solvents: pyridine and chloroform were used in the synthesis and not tested in the API.  “Further efforts are made to improve the process.”

Dr. Pogány - WHO, Shanghai 25/35 CRITICAL API DEFICIENCIES  Individual impurity limits were not based on batch analysis results and they were not in line with the ICH guidelines (e.g., NMT 1.0% instead of NMT 0.1%).  The preparation and quality specification of primary (absolute) and secondary (working) standards were not described. Analytical validation information - including experimental data for the analytical procedures used for testing the API and impurities - were not provided.

Dr. Pogány - WHO, Shanghai 26/35 CRITICAL API DEFICIENCIES  Forced degradation studies were not done :  to document the intrinsic stability of the molecule (sensitivity of the API to potential effects of the external environment – selection of containers)  to identify the likely degradants for demonstration of the stability-indicating power of assay method for the stability studies of the FPP  Available stability data revealed possible degradation and justified only a one (1) year re-test date.

Dr. Pogány - WHO, Shanghai 27/35 CRITICAL FPP DEFICIENCIES  Pharmaceutical R + D data were only exceptionally submitted. When provided, they did not capture the failures.  A dissolution method was not integrated in the quality control and stability programs.  A tabulated summary of the compositions of the pivotal (clinical, bioequivalence and validation) FPP batches and presentation of the relevant dissolution profiles were not provided. Batch size!!!

Dr. Pogány - WHO, Shanghai 28/35 CRITICAL FPP DEFICIENCIES  Documented evidence was not provided that packaging materials had been selected to ensure the quality of the FPP throughout its shelf life.  Validation reports were not provided on pilot batches and the first three production scale baches.  Annual quality review data and analysis were not submitted.

Dr. Pogány - WHO, Shanghai 29/35 SPECIFICATION DEFICIENCIES  The maximum acceptable deviation in the API content of the FPP was frequently reported as ±10% of the label claim at batch release.  Degradation products were not reported and justificatication was not offered for their absence.  Analytical methods were frequently not validated, or not properly validated, or not verified.  Microbiological purity was not tested (skip testing)

Dr. Pogány - WHO, Shanghai 30/35 STABILITY DEFICIENCIES  A systematic approach was not adopted in the presentation and evaluation of the stability information, which did not include results from the physical, chemical, biological and microbiological tests, and excluded particular attributes of the dosage form (e.g., dissolution rate for solid oral dosage forms, hardness of tablets, LOD, etc.).  Data for all attributes were not organized separately and each attribute was not evaluated in the report.  Shelf life acceptance criteria were not derived from consideration of all available stability information.

Dr. Pogány - WHO, Shanghai 31/35 HEALTH INFORMATION DEFICIENCIES  A Summary of Product Characteristics (SmPC) – aimed at medical practitioners and other health professionals and approved by the competent authority at the time of licensing– was not submitted, a major deficiency when an innovator product does not exist, e.g., generic ARV FDCs.  The package inserts distributed to the patients were not in conformity with the SmPC and the stability results (e.g., storage conditions).

Dr. Pogány - WHO, Shanghai 32/35 Main points again 1. When a multisource FPP does not meet requirements for pharmaceutical equivalence, then it is not interchangeable with the innovator FPP. 2. Many ARV APIs are not yet official in internationally used major pharmacopoeias and specifications have to be developed in house, including reference standards, validated analytical methods for assay and impurity tests. 3. For FDC FPPs without innovator product, pharmaceutical R + D rather than pharmaceutical equivalence should be demonstrated.

Dr. Pogány - WHO, Shanghai 33/35 Main points again 4. Regulatory requirements of NDRAs are not commensurate with those of the international standards of WHO. 5. ARV FPPs had been on the market for years but most of them did not meet basic standards of quality at the beginning of the project. 6. Lack of SmPC for health professionals and leaflets for patients information are critical deficiencies in case of FPPs without innovator product.

Dr. Pogány - WHO, Shanghai 34/35 CONCLUSIONS 7. It takes time to get into compliance  Develop new formulations  Data to be generated, tests carried out  GMP upgrade needed 8. Success with antiretroviral FPPs justifies joint efforts of manufacturers and WHO

Dr. Pogány - WHO, Shanghai 35/35 THANK YOU 谢谢 !